Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
Conditions
Brief summary
This phase II trial studies how well Linifanib works in treating patients with advanced, refractory colorectal cancer expressing k-Ras mutations. Linifanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Detailed description
PRIMARY OBJECTIVES: I. To achieve an overall response rate of 15% or more. SECONDARY OBJECTIVES: I. Determine progression free survival. II. Determine overall survival. III. Evaluate toxicity profile of ABT 869 (linifanib) in this patient population. OUTLINE: Patients receive Linifanib orally (PO) once daily (QD). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 30 days, every 3 months for 2 years, and then every 6 months for 3 years.
Interventions
DRUGlinifanib
Given PO
Sponsors
Vanderbilt-Ingram Cancer Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically confirmed colorectal cancer refractory to at least 1 but no more than 3 systemic chemotherapy regimens * Patients must have received one standard chemotherapy regimen in the metastatic setting * Established Ras-mutant tumor status (archived specimens are okay and this test can have been performed at local laboratories) * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 * The subject must have adequate bone marrow and organ function, defined as follows: * Hemoglobin ≥ 9g/dL * Platelets \>100,000, * Absolute neutrophil count (ANC) \> 1000/uL, * Serum creatinine \< 1.5 x upper limit of normal, * Total bilirubin \< 1.5 x the upper limit of normal, * AST and ALT ≤ 2.0 x upper limit of normal (or ≤ 5 x ULN in the presence of liver metastases) * Measurable disease, defined as at least 1 unidimensionally measurable lesion on a computed tomography (CT) scan or magnetic resonance imaging (MRI) as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 * Female subjects of childbearing potential must have a negative urine or serum pregnancy test within 7 days of study treatment; surgically sterile and/or postmenopausal women must be amenorrheic for at least 12 months to be considered of non-child-bearing potential * Female subjects of child-bearing potential and male subjects must agree to use adequate contraception prior to study entry, for the duration of study participation and up to two months after the last dose of ABT 869; adequate contraception methods should be used consistently and correctly and include the following: * Total abstinence from sexual intercourse (minimum one complete menstrual cycle) * A vasectomized partner * Hormonal contraceptives (oral, parenteral or transdermal) for at least 3 months prior to study drug administration * Double-barrier method (condoms, contraceptive sponge, diaphragm or vaginal ring with spermicidal jellies or cream) * The subject must be willing and able to comply with the protocol for the duration of the study, including undergoing treatment and scheduled visits and examinations * The subject must have given written informed consent prior to the initiation of any screening or study-specific procedures * Ability to understand and the willingness to sign a written informed consent; a signed informed consent must be obtained prior to any study-specific procedures * Patients must be at least 14 days status post last day of prior chemotherapy (at least 28 days since last dose of bevacizumab) and have recovered to grade =\< 1 from all chemotherapy-associated side effects * Patients must have the ability to swallow pills
Exclusion criteria
* Untreated central nervous system (CNS) metastases; patients may have CNS metastases from any timeframe as long as they are treated and not progressing; brain imaging is not required if there is no clinical suspicion of brain metastases * Pregnant or lactating females are excluded * Uncontrolled hypertension defined as systolic blood pressure (BP) \> 140 and/or diastolic BP \> 90 initially evaluated on day of study eligibility determination (when laboratory parameters are assessed), but must be maintained on day of study initiation; (If a patient is found to have a value outside the range above, repeat BP may be assessed and if at subsequent readings x 2 (taken in clinic at least 15 minutes apart) criteria are met, the patient can then be eligible; initiation or modification of antihypertensives is allowed to achieve adequate BP for eligibility; finally, in the case that subsequent determinations are required, the BP assessment that counts towards eligibility is the reading on the day of study initiation); (note: a clinic BP reading without the patient having been at rest for 15 minutes or with the wrong cuff size can be repeated the same day for eligibility criteria to be determined * Active bleeding or history of bleeding from cancer related events * History of cerebral vascular accident (CVA) or transient ischemic attack (TIA) or recent myocardial infarction (MI) (\< 6 months) * Active ulcerative colitis, Crohn's disease or Celiac disease that could interfere with the absorption of the drug * Current use of therapeutic anticoagulation; low dose anticoagulation for catheter prophylaxis is permitted; Lovenox is permitted for prophylaxis; (Note: patients who develop thrombosis and are placed on anticoagulation while on this trial may continue on study at the discretion of the investigator) * The subject has had major surgery within 28 days of Study Day 1 * The subject has had radiation therapy within 14 days of Study Day 1 * The subject had prior bevacizumab within 28 days of study day 1 * No prior treatment with vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitors; prior treatment with other investigational agents is allowed * The subject has a medical condition, which in the opinion of the study investigator, places them at unacceptably high risk for toxicities * Other active malignancy for which the patient has been treated within the past one year * Subjects with known human immunodeficiency virus (HIV) infection are excluded * Subject has documented left ventricular ejection fraction (LVEF) \< 50% * Subject has Proteinuria \> grade 1 at baseline measured by urine dipstick (2+ or greater) and confirmed by 24 hour (hr) urine collection (\> = 1g/24hrs)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Response Rate (Complete Response + Partial Response) With a Target of at Least 15% | Baseline and every 8 weeks, up to 2 years | Per Response Evaluation in Solid Tumors (RECIST) criteria v. 1.1: measurable lesions: complete response (CR) disappearance of target lesions, partial response (PR) \> 30% decrease in the sum of the longest diameter (LD) of target lesions, progressive disease (PD) \> 20% increase in the sum of the LD of target lesions or appearance of new lesions, stable disease (SD) neither sufficient decrease nor increase of the sum of smallest sum of the LD of target lesions. Defined as the CR + PR recorded from the start of the treatment until disease progression/recurrence, the exact two-sided 95% confidence intervals will be reported. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free Survival | Every 3 months, up to 2 years | Estimated probable duration of life without disease progression, from on-study date to earlier of progression date or date of death from any cause, using the Kaplan-Meier method with censoring. Disease progression is defined under RECIST v1.1 as \>=20% increase in sum of longest diameters of target lesions, unequivocal progression of non-target lesions, or appearance of new lesions. |
| Overall Survival | Every 3 months, up to 2 years | Estimated probable duration of life from on-study date to date of death from any cause, using the Kaplan-Meier method with censoring. |
| Number of Patients With Each Worst-Grade Toxicity | date on-study up to 2 years following final dose of study | Count of patients according to the worst-grade toxicity experienced by each, where worst-grade toxicity is per NCI common toxicity criteria: grade 1= mild; grade 2 = moderate; grade 3 = severe; grade 4 = life-threatening; grade 5 = death Assessed: days 1 &15 of cycle 1; day 1 of each subsequent 28-day cycle; at 30-day follow-up for two years |
Countries
United States
Participant flow
Recruitment details
This study opened June 3, 2011 and continued until June 3, 2013. Patients were enrolled at Vanderbilt-Ingram Cancer Center.
Pre-assignment details
Thirty-five patients consented to be on this study. Four patients were considered ineligible, and 1 patient withdrew prior to treatment.
Participants by arm
| Arm | Count |
|---|---|
| Treatment (Enzyme Inhibitor) Patients receive linifanib PO QD. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. | 30 |
| Total | 30 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Adverse Event | 3 |
| Overall Study | disease progression | 18 |
| Overall Study | other complicating disease | 1 |
| Overall Study | pt did not get tx, nausea/vomiting | 1 |
| Overall Study | Withdrawal by Subject | 7 |
Baseline characteristics
| Characteristic | Treatment (Enzyme Inhibitor) |
|---|---|
| Age, Customized Age 20-29 | 1 participants |
| Age, Customized Age 40-49 | 4 participants |
| Age, Customized Age 50-59 | 10 participants |
| Age, Customized Age 60-69 | 10 participants |
| Age, Customized Age 70-79 | 5 participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 2 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 24 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 4 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 1 Participants |
| Race (NIH/OMB) Black or African American | 3 Participants |
| Race (NIH/OMB) More than one race | 2 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 24 Participants |
| Region of Enrollment United States | 30 participants |
| Sex: Female, Male Female | 14 Participants |
| Sex: Female, Male Male | 16 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 29 / 30 |
| serious Total, serious adverse events | 16 / 30 |
Outcome results
Primary
Overall Response Rate (Complete Response + Partial Response) With a Target of at Least 15%
Per Response Evaluation in Solid Tumors (RECIST) criteria v. 1.1: measurable lesions: complete response (CR) disappearance of target lesions, partial response (PR) \> 30% decrease in the sum of the longest diameter (LD) of target lesions, progressive disease (PD) \> 20% increase in the sum of the LD of target lesions or appearance of new lesions, stable disease (SD) neither sufficient decrease nor increase of the sum of smallest sum of the LD of target lesions. Defined as the CR + PR recorded from the start of the treatment until disease progression/recurrence, the exact two-sided 95% confidence intervals will be reported.
Time frame: Baseline and every 8 weeks, up to 2 years
Population: All patients are included in the analysis on intention-to-treat basis. Analysis is by Kaplan-Meier method, where death is an event, with censoring for non-expired patients at greater of off-study date or last known alive date.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Treatment (Enzyme Inhibitor) | Overall Response Rate (Complete Response + Partial Response) With a Target of at Least 15% | 0 percentage of target lesions |
Secondary
Number of Patients With Each Worst-Grade Toxicity
Count of patients according to the worst-grade toxicity experienced by each, where worst-grade toxicity is per NCI common toxicity criteria: grade 1= mild; grade 2 = moderate; grade 3 = severe; grade 4 = life-threatening; grade 5 = death Assessed: days 1 &15 of cycle 1; day 1 of each subsequent 28-day cycle; at 30-day follow-up for two years
Time frame: date on-study up to 2 years following final dose of study
Population: Total number of patients reported with any toxicity
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Treatment (Enzyme Inhibitor) | Number of Patients With Each Worst-Grade Toxicity | worst grade toxicity 1 | 0 participants |
| Treatment (Enzyme Inhibitor) | Number of Patients With Each Worst-Grade Toxicity | worst grade toxicity 2 | 4 participants |
| Treatment (Enzyme Inhibitor) | Number of Patients With Each Worst-Grade Toxicity | worst grade toxicity 3 | 23 participants |
| Treatment (Enzyme Inhibitor) | Number of Patients With Each Worst-Grade Toxicity | worst grade toxicity 4 | 1 participants |
| Treatment (Enzyme Inhibitor) | Number of Patients With Each Worst-Grade Toxicity | worst grade toxicity 5 | 1 participants |
Secondary
Overall Survival
Estimated probable duration of life from on-study date to date of death from any cause, using the Kaplan-Meier method with censoring.
Time frame: Every 3 months, up to 2 years
Population: All patients are included in the analysis on intention-to-treat basis. Analysis is by Kaplan-Meier method, where death is an event, with censoring for non-expired patients at greater of off-study date or last known alive date.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Treatment (Enzyme Inhibitor) | Overall Survival | 290 days |
Secondary
Progression-free Survival
Estimated probable duration of life without disease progression, from on-study date to earlier of progression date or date of death from any cause, using the Kaplan-Meier method with censoring. Disease progression is defined under RECIST v1.1 as \>=20% increase in sum of longest diameters of target lesions, unequivocal progression of non-target lesions, or appearance of new lesions.
Time frame: Every 3 months, up to 2 years
Population: All patients are included in the analysis on intention-to-treat basis. Analysis is by Kaplan-Meier method, where either death or progression is an event, with censoring for non-progressed, non-expired patients at greater of off-study date or last known alive date.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Treatment (Enzyme Inhibitor) | Progression-free Survival | 155 days |